Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX-904 in Advanced Solid Tumors
NCT05387265Phase 1Terminated
- Sponsor
- CytomX
- Start
- May 2022
- Primary completion
- Jun 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CX-904 in solid tumor, sponsored by CytomX. Primary endpoint: Patients Experiencing Dose-limiting Toxicity at 12 months. Started May 2022; status: terminated.
02
Drugs
CX-904
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05387265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387265.